سعر ابيستجمين 2.5مجم/مل فيال 2024

Neostigmine methylsulphate 2.5 mg/1 ml injection for subcutaneous, intramuscular or slow intravenous use, 1 vial (Eipico).

• Directory indication: treatment of myasthenia gravis.

• Most common adverse reactions: bradycardia, nausea and vomiting.General active-ingredient information · DailyMed (U.S. NLM)

• Known hypersensitivity to neostigmine methylsulfate; peritonitis or mechanical obstruction of the intestinal or urinary tract.General active-ingredient information · DailyMed (U.S. NLM)

• Neostigmine has been associated with bradycardia; an anticholinergic (e.g. atropine sulfate or glycopyrrolate) should be given before or with neostigmine. Use with caution in coronary artery disease, cardiac arrhythmias, recent acute coronary syndrome or myasthenia gravis.General active-ingredient information · DailyMed (U.S. NLM)

• No adequate or well-controlled studies in pregnant women; use only if clearly needed.General active-ingredient information · DailyMed (U.S. NLM)
• Not studied in lactating women; unknown whether present in human milk; weigh breastfeeding benefits against the mother's need.General active-ingredient information · DailyMed (U.S. NLM)

English text not available for this section.